First Home-Use Trial of the iLet Bionic Pancreas System Using Pre-Filled Cartridges of Dasiglucagon Compatible With iLet Has Been Successfully Completed

Boston, MA and Copenhagen, Denmark - June 6,2019 - Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL) announced today that a home-use study of dasiglucagon in the iLet Bionic Pancreas System has been successfully completed.

Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet® bionic pancreas using dasiglucagion.